Fundamental Analysis of IMMIX BIOPHARMA INC(NASDAQ:IMMX) stock

Fundamental Rating

IMMX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. The financial health of IMMX is average, but there are quite some concerns on its profitability. IMMX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

IMMX had negative earnings in the past year.

IMMX had a negative operating cash flow in the past year.

In the past 5 years IMMX always reported negative net income.

IMMX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -87.07%, IMMX is doing worse than 71.68% of the companies in the same industry.

IMMX has a worse Return On Equity (-124.73%) than 60.18% of its industry peers.

		Industry Rank	Sector Rank
ROA	-87.07%
ROE	-124.73%
ROIC	N/A

ROA(3y)-88.88%

ROA(5y)-116.56%

ROE(3y)-97.36%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IMMX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for IMMX has been increased compared to 1 year ago.

There is no outstanding debt for IMMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -1.45, we must say that IMMX is in the distress zone and has some risk of bankruptcy.

IMMX has a Altman-Z score (-1.45) which is comparable to the rest of the industry.

IMMX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-1.45

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

IMMX has a Current Ratio of 3.47. This indicates that IMMX is financially healthy and has no problem in meeting its short term obligations.

IMMX has a Current ratio (3.47) which is comparable to the rest of the industry.

A Quick Ratio of 3.47 indicates that IMMX has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.47, IMMX is in line with its industry, outperforming 43.72% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.47
Quick Ratio	3.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 7.22% over the past year.

EPS 1Y (TTM)7.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.35%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 38.87% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y25.82%

EPS Next 2Y16.73%

EPS Next 3Y16.25%

EPS Next 5Y38.87%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IMMX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year IMMX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IMMX's earnings are expected to grow with 16.25% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.73%

EPS Next 3Y16.25%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IMMX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IMMIX BIOPHARMA INC

NASDAQ:IMMX (12/20/2024, 8:18:24 PM)

2.17

-0.05 (-2.25%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/amc

Earnings (Next)N/A N/A

Inst Owners14.04%

Inst Owner Change-6.88%

Ins Owners28.37%

Ins Owner Change0.53%

Market Cap59.70M

Analysts82.86

Price Target7.14 (229.03%)

Short Float %3.01%

Short Ratio2.8

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-8.54%

Min EPS beat(2)-47.06%

Max EPS beat(2)29.97%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)36.36%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	3.4
P/tB	3.4
EV/EBITDA	N/A

EPS(TTM)-0.88

EYN/A

EPS(NY)-0.56

Fwd EYN/A

FCF(TTM)-0.6

FCFYN/A

OCF(TTM)-0.57

OCFYN/A

SpS0

BVpS0.64

TBVpS0.64

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-87.07%
ROE	-124.73%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-88.88%

ROA(5y)-116.56%

ROE(3y)-97.36%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	3832.79%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.47
Quick Ratio	3.47
Altman-Z	-1.45

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)7.22%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.35%

EPS Next Y25.82%

EPS Next 2Y16.73%

EPS Next 3Y16.25%

EPS Next 5Y38.87%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-58.51%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-33.63%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-257.55%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-242.74%

OCF growth 3YN/A

OCF growth 5YN/A

IMMIX BIOPHARMA INC (IMMX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens